14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly
Retrieved from Vance, C
Experts remain skeptical
Semaglutide Tirzepatide Mechanism of Action Semaglutide belongs to a class of medications called GLP-1 receptor agonists
Next, lets tackle itching and skin irritation
Side Effects Change in how much or how often you urinate, lower back or side pain, blood in your urine Unusual moods or behaviors, depression, thoughts of hurting yourself or others Blurred vision or any other change in vision Warnings Tell your doctor if you are breastfeeding, or if you have kidney disease, pancreas problems, diabetes, digestion problems (including gastroparesis), or a history of diabetic retinopathy or depression